NCT05719779 Tolerance and Benefits of Mandibular Advanced Device for Snoring and Sleep Apnea in Oropharyngeal Cancer.
| NCT ID | NCT05719779 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre hospitalier de l'Université de Montréal (CHUM) |
| Condition | Oral Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 35 participants |
| Start Date | 2023-02-03 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 35 participants in total. It began in 2023-02-03 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Evaluation of the Tolerance and Benefits of Mandibular Advanced Device (MAD) for Snoring and Sleep Apnea in Patients with Oropharyngeal Cancer (OPC): Mixed Design Study.
Eligibility Criteria
Inclusion Criteria: * oropharyngeal cancer diagnosis * 18 years of age and over * female or male; ratio of 1/4 toward men * had received RTH in the Department of Radiation Oncology, * reporting snoring and/or respiratory cessation complaints during sleep, Exclusion Criteria: * pregnant or breastfeeding woman; * edentation preventing retention of the oral appliance; * taking opioid or anxiolitic type medications; * history of major depression, * uncontrolled hypertension, * history of stroke; * under treatment with CPAP for sleep apnea; * regular and intense orofacial pain; * under pharmacological treatment for insomnia; * excessive alcohol or drug use (e.g., cannabis, opioid).
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05719779 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Oral Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05719779 currently recruiting?
Yes, NCT05719779 is actively recruiting participants. Contact the research team at gilles.lavigne@umontreal.ca for enrollment information.
Where is the NCT05719779 trial being conducted?
This trial is being conducted at Montreal, Canada.
Who is sponsoring the NCT05719779 clinical trial?
NCT05719779 is sponsored by Centre hospitalier de l'Université de Montréal (CHUM). The trial plans to enroll 35 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.